Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease, but the impact on CV risk varies by lipid disorder. Treatment has centered mainly on reducing the levels of atherogenic lipids, but physicians are increasingly seeking evidence of CV outcomes benefits. Numerous treatments are available, but few have solid evidence of CV benefit, and therapeutic approaches can vary. The recent launches of the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which are expected to deliver clinically meaningful improvements in outcomes, will reshape the current treatment paradigm.


Related Reports

Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast

Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD). Current lipid-modifying therapies, including statins, ezetimibe, fibrates,...

View Details

Dyslipidemia - Current Treatment - Detailed, Expanded Analysis: Physician Insights (US) : Hypertriglyceridemia

Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels,...

View Details